Affections non-directement attribuables à la sclérodermie systémique (ANDAS) diagnostiquées au cours du suivi dans un centre de compétence: à propos d'une cohorte de 200 patients

Archive ouverte

Lepart, C | Ardois, S | Bismut, M | Ballerie, A | Cazalets, C | Coiffier, G | Jego, P | Belhomme, N | Lescoat, A

Edité par CCSD ; Elsevier -

National audience. Introduction - Our work aimed to investigate the illnesses unrelated to systemic sclerosis (IUSS), diagnosed among patients with systemic sclerosis (SSc) throughout their follow-up in a referral tertiary care center. Methods - All the patients with SSc followed in the Internal Medicine Department of the University Hospital between October, 2014 and December, 2015, were included. We specifically reviewed the medical records of the patients who exhibited IUSS, defined as an illness that could not be considered as a typical clinical manifestation or as a usual complication of the disease. Results - Two hundred patients were included, and 38 IUSS were diagnosed among 31 SSc patients, over a 4 years median follow-up period. These diagnoses included vascular diseases (26%), heart diseases (21%), neoplasia (8%), infectious diseases (6%), autoimmune diseases (5%), endocrinopathies (5%), and others (24%). The median follow-up time before IUSS diagnosis was two years. Seventeen (45%) of these diagnoses were considered in patients showing suggestive clinical signs. A specific therapy was delivered in 25 cases (66%). Group comparisons revealed that dyslipidemia was more frequent in patients with IUSS (OR = 2.6 [1.1-1.5]; p = 0.014), while no differences were found for the other characteristics. Especially, no association between auto-antibodies specificity and the occurrence of IUSS was found. Conclusion - This study focused on IUSS in SSc patients and highlights the need for a polyvalent clinical approach all along the follow up of SSc patients.

Suggestions

Du même auteur

Drug-induced granulomatosis is dupilumab the new kid on the block?

Archive ouverte | Belhomme, N | CCSD

International audience. Dupilumab is an IgG4 antibody directed toward IL-4 and IL-13, two major effectors of the Th2 immunity response. It was originally developed for severe and/or refractory atopic dermatitis, nev...

Libman-Sacks endocarditis under apixaban in a patient with a high-risk profile venous antiphospholipid syndrome. Une endocardite de Libman-Sacks survenant sous apixaban chez une patiente atteinte de SAPL veineux de profil à haut risque

Archive ouverte | Allain, J-S | CCSD

National audience. INTRODUCTION: Libman-Sacks endocarditis is a rare complication of antiphospholipid syndrome. Anti-vitamin K therapy is the standard treatment, although valvular replacement surgery may be required...

Gestion de l’incertitude et compétence médicale : une réflexion clinique et pédagogique [Uncertainty management and medical skills A clinical and educational reflexion]

Archive ouverte | Belhomme, N | CCSD

National audience

Chargement des enrichissements...